{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:55:47Z","timestamp":1791374147874,"version":"4.3.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/eurheartj\/ehag720","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:38:35Z","timestamp":1791286715000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond the sarcomere: copper chelation in hypertrophic cardiomyopathy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-8495","authenticated-orcid":false,"given":"Anjali Tiku","family":"Owens","sequence":"first","affiliation":[{"name":"Division of Cardiology, Center for Inherited Cardiovascular Disease, University of Pennsylvania Perelman School of Medicine , 3400 Civic Center Blvd, PCAM South Tower 11th floor, Philadelphia, PA 19104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2026100707324000600_ehag720-B1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2026100707324000600_ehag720-B2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026100707324000600_ehag720-B3","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026100707324000600_ehag720-B4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026100707324000600_ehag720-B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026100707324000600_ehag720-B6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100707324000600_ehag720-B7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100707324000600_ehag720-B8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/NEJMoa2505927","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy","volume":"393","author":"Desai","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100707324000600_ehag720-B9"},{"key":"2026100707324000600_ehag720-B10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag512","article-title":"Trientine for hypertrophic cardiomyopathy: a phase 2 trial","volume":"47","author":"Farrant","year":"2026","journal-title":"Eur Heart J"},{"key":"2026100707324000600_ehag720-B11","doi-asserted-by":"publisher","author":"Chen","DOI":"10.1038\/s41392-022-01229-y"},{"key":"2026100707324000600_ehag720-B12","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1158\/1535-7163.MCT-10-0523","article-title":"Triethylenetetramine pharmacology and its clinical applications","volume":"9","author":"Lu","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2026100707324000600_ehag720-B13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1475-2840-13-100","article-title":"Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation","volume":"13","author":"Zhang","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2026100707324000600_ehag720-B14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00125-009-1265-3","article-title":"A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study","volume":"52","author":"Cooper","year":"2009","journal-title":"Diabetologia"},{"key":"2026100707324000600_ehag720-B15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2008.04.047","article-title":"Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy","volume":"52","author":"Olivotto","year":"2008","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag720\/71662077\/ehag720.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag720\/71662077\/ehag720.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:32:49Z","timestamp":1791372769000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag720\/8875328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag720","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"ehag720"}}